Our study developed a TROP2-targeted NDC with potent cytotoxicity against TROP2-positive pancreatic cancer, offering new possibilities for the development of more effective and personalized treatments for pancreatic cancer. Here, TACSTD2 is linked to pancreatic neoplasm.